Correlation Between Prostate-specific Membrane Antigen Positron Emission Tomography and Arterial Spin Labeling Perfusion Imaging in Glioblastoma

Evaluating the relationship between prostate-specific membrane antigen positron emission tomography and arterial spin labeling perfusion imaging, and the correlation with prostate-specific membrane antigen expressed on glioblastoma microvascular.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Glioblastoma Astrocytoma Glioma Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Neuroectodermal Tumors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

The Second Hospital of Lanzhou University

Lanzhou, Gansu, 730000, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Newly diagnosed or recurrent glioblastoma;
Adult (≥18 years old);

Exclusion criteria

The patient has a serious underlying disease or mental illness and is unable to cooperate with the imaging examination;
Have received systematic chemotherapy;
The image data is of poor or incomplete quality;
pregnant women;

Treatment and study plan

glioblastoma

Diagnostic Test

All patients underwent conventional MRI, ASL perfusion imaging and 68Ga-PSMA-11 PET/CT examinations within 1 week interval

Primary outcomes

The similarity of biological information

Time frame: 2 week

Evaluating the similarity of biological information captured by prostate-specific membrane antigen positron emission tomography and arterial spin labeling perfusion imaging in glioblastoma.

Sponsors and collaborators

Lead sponsor

Lanzhou University Second Hospital

Other

Registry information

Official study title

Similarity of Biological Information Captured by (68)Gallium-prostate Specific Membrane Antigen-11 Positron Emission Tomography and Arterial Spin Labeling Perfusion Imaging in Glioblastoma

Acronym: PSMA，ASL，PET

Important dates

Study start: 2022
Primary completion: 2024
Study completion: 2024
First posted: Sep 19, 2024
Registry last updated: Sep 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed